A Study Evaluating Sotorasib Platinum Doublet Combination Versus

CodeBreaK 202 tests sotorasib+chemo vs pembro+chemo 1L in KRAS G12C nonsquamous NSCLC (PD-L1<50%). Sotorasib monotherapy showed modest PFS benefit in 2L (CodeBreaK 200) but combo with chemo lacks strong precedent; hepatotoxicity concerns with prior IO exposure led to design excluding recent IO. Beating pembro+chemo on PFS is a high bar—KEYNOTE-189 set strong benchmark. Amgen powered for PFS/OS but risk of modest/null effect meaningful. Primary completion still ~1.5 yrs out.

Sotorasib plus chemotherapy has a plausible efficacy rationale, but beating pembrolizumab plus chemotherapy in untreated advanced NSCLC is a demanding active-control test. BICR-assessed PFS is robust, yet no supportive randomized frontline data are provided, and recruitment remains ongoing.

Randomized phase 3 with BICR PFS is a rigorous endpoint, but sotorasib plus chemotherapy must outperform an established pembrolizumab-chemotherapy front-line regimen. Advanced nonsquamous disease is heterogeneous, and efficacy/safety integration and long follow-up add execution and disclosure risk.

This randomized Phase 3 trial uses a strong PFS endpoint with RECIST v1.1 and blinded independent central review. However, the sotorasib combination must outperform an active pembrolizumab-platinum comparator, while no efficacy or operational signals are disclosed. Recruiting status and 554 days to completion add execution and disclosure uncertainty.

Phase 3, front-line nonsquamous NSCLC, PFS primary by BICR. Sotorasib+platinum doublet vs pembro+platinum doublet; sotorasib KRAS G12C-specific with established 2L activity but no strong 1L superiority signals vs IO-chemo standard. Long timeline to 2028 readout adds execution/disclosure risk.

CodeBreaK 202 compares sotorasib + chemo vs pembro + chemo in 1L KRAS G12C-mutated, PD-L1 negative NSCLC. Phase 1b data (CodeBreaK 101) showed an impressive 11.9-month mPFS in this cohort, well above the ~6.2-month historical benchmark for the control arm (Keynote-189). With BICR mitigating open-label bias and a strong efficacy margin, the PFS endpoint is highly likely to succeed.

Phase 3 head-to-head vs pembrolizumab+chemo in 1L NSCLC is a high bar. Sotorasib's 2L PFS benefit was modest (HR 0.66) and durability limited. Biomarker selection (KRAS G12C) may help, but chemo combo must beat a proven standard. Probability of superiority on PFS is below even odds.

Phase 3 head-to-head vs pembro+platinum doublet, a strong first-line NSCLC standard. Sotorasib has shown activity in KRAS G12C pretreated patients, but beating an IO+chemo backbone on PFS is a high bar. KRAS G12C population may favor targeted therapy, but pembro+chemo efficacy in this subgroup is still meaningful. Trial is early (recruiting, 554 days to completion), adding uncertainty. Historical Phase 3 oncology success vs active comparator is modest.

CodeBreaK 202 tests sotorasib+chemo vs pembrolizumab+chemo in KRAS G12C NSCLC. Sotorasib has strong Phase 2 data (CodeBreaK 100). However, beating immuno-chemo (standard of care) in first-line is difficult. KRAS G12C is a small subset; statistical power and heterogeneity are risks. Modest edge for YES based on targeted efficacy, but high uncertainty remains.

Sotorasib showed PFS benefit in second‑line KRAS‑G12C NSCLC, but front‑line pembrolizumab + chemo is established with strong PFS. Adding an unproven KRAS inhibitor to chemo raises toxicity and uncertain additive benefit, making a statistically significant PFS win slightly below 50%.

Sotorasib (KRAS G12C inhibitor) plus chemo vs pembrolizumab plus chemo in 1L NSCLC. Pembrolizumab-chemo is established standard of care with proven PFS benefit. Sotorasib monotherapy showed modest benefit in pretreated KRAS G12C NSCLC; combining with chemo in 1L is unproven. No prior positive Phase 3 data for this combination. Long timeline (554 days) adds execution risk. Market asks only PFS, not OS—PFS is easier to hit but control arm is strong. Amgen's track record is solid but this is a challenging comparator.

CodeBreaK 202 pits sotorasib+chemo vs pembrolizumab+chemo in 1L nonsquamous NSCLC. Sotorasib only benefits KRAS G12C+ patients (~13% of NSCLC); trial likely biomarker-restricted but disclosure risk remains. KRAS G12C tumors historically show lower immunotherapy response, which could help sotorasib arm, but pembro+chemo (KEYNOTE-189 HR ~0.52) is a strong, established comparator. PFS readout ~18 months out. Modest probability of positive PFS given high bar and biomarker dependency.